FY2028 EPS Estimates for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reduced by Analyst

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Research analysts at HC Wainwright dropped their FY2028 earnings estimates for shares of BioCryst Pharmaceuticals in a research report issued on Tuesday, May 7th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings of $1.31 per share for the year, down from their previous estimate of $1.32. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.69) per share.

Several other research firms have also weighed in on BCRX. Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. JMP Securities increased their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a report on Tuesday. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $14.00.

BioCryst Pharmaceuticals Price Performance

BCRX stock opened at $5.10 on Wednesday. The firm has a market cap of $1.05 billion, a PE ratio of -4.77 and a beta of 1.96. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $8.96. The firm has a 50 day simple moving average of $4.89 and a 200 day simple moving average of $5.45.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The firm had revenue of $92.80 million for the quarter, compared to analyst estimates of $85.62 million. During the same period in the previous year, the firm earned ($0.28) earnings per share. The company’s revenue for the quarter was up 34.9% on a year-over-year basis.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. raised its position in shares of BioCryst Pharmaceuticals by 96.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 2,388 shares in the last quarter. Teacher Retirement System of Texas grew its stake in shares of BioCryst Pharmaceuticals by 4.9% during the third quarter. Teacher Retirement System of Texas now owns 53,640 shares of the biotechnology company’s stock worth $380,000 after buying an additional 2,519 shares during the last quarter. Fifth Third Bancorp grew its stake in shares of BioCryst Pharmaceuticals by 17,500.0% in the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 3,500 shares during the last quarter. ProShare Advisors LLC grew its stake in shares of BioCryst Pharmaceuticals by 9.1% in the first quarter. ProShare Advisors LLC now owns 48,503 shares of the biotechnology company’s stock worth $246,000 after purchasing an additional 4,041 shares during the last quarter. Finally, Teza Capital Management LLC boosted its position in BioCryst Pharmaceuticals by 12.8% during the third quarter. Teza Capital Management LLC now owns 36,904 shares of the biotechnology company’s stock valued at $261,000 after acquiring an additional 4,180 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.